Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent W Mouw

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
Cancer Research|September 2, 2020
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder CancerJoaquim Bellmunt, Jaegil Kim, Brendan Reardon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancerIlana B Epstein, Adetolani Odogiyon, Stephanie Berg, et al.
European Urology|February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Roger Li, Patrick J Hensley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder CancerSophia C Kamran, Yuzhen Zhou, Keisuke Otani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerQiang Li, Alexis W Damish, Zoë Frazier, et al.
Biorxiv : the Preprint Server for Biology|April 27, 2026
KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress SensitivityAlexander C-Y Tsai, Mathew D Lin, Vinesh T Puliyappadamba, et al.
Science Advances|November 22, 2023
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancerYuzhen Zhou, Judit Börcsök, Elio Adib, et al.
European Urology Oncology|March 25, 2020
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific DifferencesJoep J de Jong, Joost L Boormans, Bas W G van Rhijn, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancerFilipe Lf Carvalho, Jihyun Lee, Nikolaos Kalavros, et al.
Oncogene|May 28, 2020
EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repairAllyson E Koyen, Matthew Z Madden, Dongkyoo Park, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Cancer Research|September 2, 2020
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder CancerJoaquim Bellmunt, Jaegil Kim, Brendan Reardon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancerIlana B Epstein, Adetolani Odogiyon, Stephanie Berg, et al.
European Urology|February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Roger Li, Patrick J Hensley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder CancerSophia C Kamran, Yuzhen Zhou, Keisuke Otani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerQiang Li, Alexis W Damish, Zoë Frazier, et al.
Biorxiv : the Preprint Server for Biology|April 27, 2026
KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress SensitivityAlexander C-Y Tsai, Mathew D Lin, Vinesh T Puliyappadamba, et al.
Science Advances|November 22, 2023
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancerYuzhen Zhou, Judit Börcsök, Elio Adib, et al.
European Urology Oncology|March 25, 2020
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific DifferencesJoep J de Jong, Joost L Boormans, Bas W G van Rhijn, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancerFilipe Lf Carvalho, Jihyun Lee, Nikolaos Kalavros, et al.
Oncogene|May 28, 2020
EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repairAllyson E Koyen, Matthew Z Madden, Dongkyoo Park, et al.
Pageof 13